-
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
Østergaard, M., van Vollenhoven, R. F., Rudin, A., Hetland, M. L., Heiberg, M. S., Nordström, D. C., Nurmohamed, M. T., Gudbjornsson, B., Ørnbjerg, L. M., Bøyesen, P., Lend, K., Hørslev-Petersen, K., Uhlig, T., Sokka, T., Grondal, G., Krabbe, S., Lindqvist, J., Gjertsson, I., Glinatsi, D., Kapetanovic, M. C., & 25 others , 2023, (E-pub ahead of print) In: Annals of the rheumatic diseases.Research output: Contribution to journal › Article › Academic › peer-review
-
Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial
Lend, K., van Vollenhoven, R. F., Lampa, J., Lund Hetland, M., Haavardsholm, E. A., Nordström, D., Nurmohamed, M., Gudbjornsson, B., Rudin, A., Østergaard, M., Uhlig, T., Grondal, G., Hørslev-Petersen, K., Heiberg, M. S., Sokka-Isler, T., Koopman, F. A., Twisk, J. W. R. & van der Horst-Bruinsma, I., 1 Oct 2022, In: The Lancet Rheumatology. 4, 10, p. e688-e698Research output: Contribution to journal › Article › Academic › peer-review
- All publications